Utility valuations for outcome states of colorectal cancer

Reid M. Ness, Ann M. Holmes, Robert Klein, Robert Dittus

Research output: Contribution to journalArticle

114 Citations (Scopus)

Abstract

OBJECTIVE: Utilities for the outcome states of colorectal cancer (CRC) must be measured to evaluate the cost-utility of screening and surveillance strategies for this disease. We sought to measure utilities for stage- dependent outcome states of CRC. METHODS: We identified persons who had previously undergone removal of colorectal adenoma. We conducted individual interviews in which these participants were presented with stage-dependent outcome states and were asked to assess utilities for them using the standard gamble technique. RESULTS: A total of 90 participants were interviewed; nine were excluded, leaving 81 for analysis. We obtained the following utility valuations: stage I rectal or stage I/II colon cancer (mean 0.74, median 0.75); stage III colon cancer (mean 0.67, median 0.75); stage II/III rectal cancer without ostomy (mean 0.59, median 0.60), stage II/III rectal cancer with ostomy (mean 0.50, median 0.55), stage IV rectal or colon cancer (mean 0.25, median 0.20). These valuations were statistically different from each other. CONCLUSIONS: We measured utilities for stage-dependent outcome states of CRC in a sample of persons who had previously undergone removal of colorectal adenoma. We found that our participants were able to differentiate between the presented outcome states and assigned lower utility to increasingly morbid states. Our results show that stage-dependent morbidity is an important consideration in CRC and should be incorporated into any decision analysis model evaluating the cost-effectiveness of CRC screening or surveillance.

Original languageEnglish (US)
Pages (from-to)1650-1657
Number of pages8
JournalAmerican Journal of Gastroenterology
Volume94
Issue number6
DOIs
StatePublished - Jun 1 1999

Fingerprint

Colorectal Neoplasms
Rectal Neoplasms
Ostomy
Colonic Neoplasms
Adenoma
Decision Support Techniques
Early Detection of Cancer
Cost-Benefit Analysis
Interviews
Morbidity
Costs and Cost Analysis

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Utility valuations for outcome states of colorectal cancer. / Ness, Reid M.; Holmes, Ann M.; Klein, Robert; Dittus, Robert.

In: American Journal of Gastroenterology, Vol. 94, No. 6, 01.06.1999, p. 1650-1657.

Research output: Contribution to journalArticle

Ness, Reid M. ; Holmes, Ann M. ; Klein, Robert ; Dittus, Robert. / Utility valuations for outcome states of colorectal cancer. In: American Journal of Gastroenterology. 1999 ; Vol. 94, No. 6. pp. 1650-1657.
@article{3513642274af450f86fa6908ed28d8bf,
title = "Utility valuations for outcome states of colorectal cancer",
abstract = "OBJECTIVE: Utilities for the outcome states of colorectal cancer (CRC) must be measured to evaluate the cost-utility of screening and surveillance strategies for this disease. We sought to measure utilities for stage- dependent outcome states of CRC. METHODS: We identified persons who had previously undergone removal of colorectal adenoma. We conducted individual interviews in which these participants were presented with stage-dependent outcome states and were asked to assess utilities for them using the standard gamble technique. RESULTS: A total of 90 participants were interviewed; nine were excluded, leaving 81 for analysis. We obtained the following utility valuations: stage I rectal or stage I/II colon cancer (mean 0.74, median 0.75); stage III colon cancer (mean 0.67, median 0.75); stage II/III rectal cancer without ostomy (mean 0.59, median 0.60), stage II/III rectal cancer with ostomy (mean 0.50, median 0.55), stage IV rectal or colon cancer (mean 0.25, median 0.20). These valuations were statistically different from each other. CONCLUSIONS: We measured utilities for stage-dependent outcome states of CRC in a sample of persons who had previously undergone removal of colorectal adenoma. We found that our participants were able to differentiate between the presented outcome states and assigned lower utility to increasingly morbid states. Our results show that stage-dependent morbidity is an important consideration in CRC and should be incorporated into any decision analysis model evaluating the cost-effectiveness of CRC screening or surveillance.",
author = "Ness, {Reid M.} and Holmes, {Ann M.} and Robert Klein and Robert Dittus",
year = "1999",
month = "6",
day = "1",
doi = "10.1111/j.1572-0241.1999.01157.x",
language = "English (US)",
volume = "94",
pages = "1650--1657",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Utility valuations for outcome states of colorectal cancer

AU - Ness, Reid M.

AU - Holmes, Ann M.

AU - Klein, Robert

AU - Dittus, Robert

PY - 1999/6/1

Y1 - 1999/6/1

N2 - OBJECTIVE: Utilities for the outcome states of colorectal cancer (CRC) must be measured to evaluate the cost-utility of screening and surveillance strategies for this disease. We sought to measure utilities for stage- dependent outcome states of CRC. METHODS: We identified persons who had previously undergone removal of colorectal adenoma. We conducted individual interviews in which these participants were presented with stage-dependent outcome states and were asked to assess utilities for them using the standard gamble technique. RESULTS: A total of 90 participants were interviewed; nine were excluded, leaving 81 for analysis. We obtained the following utility valuations: stage I rectal or stage I/II colon cancer (mean 0.74, median 0.75); stage III colon cancer (mean 0.67, median 0.75); stage II/III rectal cancer without ostomy (mean 0.59, median 0.60), stage II/III rectal cancer with ostomy (mean 0.50, median 0.55), stage IV rectal or colon cancer (mean 0.25, median 0.20). These valuations were statistically different from each other. CONCLUSIONS: We measured utilities for stage-dependent outcome states of CRC in a sample of persons who had previously undergone removal of colorectal adenoma. We found that our participants were able to differentiate between the presented outcome states and assigned lower utility to increasingly morbid states. Our results show that stage-dependent morbidity is an important consideration in CRC and should be incorporated into any decision analysis model evaluating the cost-effectiveness of CRC screening or surveillance.

AB - OBJECTIVE: Utilities for the outcome states of colorectal cancer (CRC) must be measured to evaluate the cost-utility of screening and surveillance strategies for this disease. We sought to measure utilities for stage- dependent outcome states of CRC. METHODS: We identified persons who had previously undergone removal of colorectal adenoma. We conducted individual interviews in which these participants were presented with stage-dependent outcome states and were asked to assess utilities for them using the standard gamble technique. RESULTS: A total of 90 participants were interviewed; nine were excluded, leaving 81 for analysis. We obtained the following utility valuations: stage I rectal or stage I/II colon cancer (mean 0.74, median 0.75); stage III colon cancer (mean 0.67, median 0.75); stage II/III rectal cancer without ostomy (mean 0.59, median 0.60), stage II/III rectal cancer with ostomy (mean 0.50, median 0.55), stage IV rectal or colon cancer (mean 0.25, median 0.20). These valuations were statistically different from each other. CONCLUSIONS: We measured utilities for stage-dependent outcome states of CRC in a sample of persons who had previously undergone removal of colorectal adenoma. We found that our participants were able to differentiate between the presented outcome states and assigned lower utility to increasingly morbid states. Our results show that stage-dependent morbidity is an important consideration in CRC and should be incorporated into any decision analysis model evaluating the cost-effectiveness of CRC screening or surveillance.

UR - http://www.scopus.com/inward/record.url?scp=0032976480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032976480&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.1999.01157.x

DO - 10.1111/j.1572-0241.1999.01157.x

M3 - Article

C2 - 10364039

AN - SCOPUS:0032976480

VL - 94

SP - 1650

EP - 1657

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 6

ER -